-
For the research and development of innovative medical devices, the financing of medical device companies is accelerating
Time of Update: 2022-08-30
At present, under a series of favorable policies, the domestic medical device industry has ushered in a broader space for development, and at the same time has embarked on the road of accelerated upgrading .
-
In order to solve the "difficulty in collecting money", the scope of direct settlement between medical insurance and pharmaceutical companies is continuing to expand!
Time of Update: 2022-08-30
[Pharmaceutical Network Industry News] Recently, the Ningxia Medical Insurance Bureau publicly solicited opinions on the "Implementation Plan for the Bargaining and Purchasing of Medicines and Medical Consumables for Medical Institutions in Ningxia Hui Autonomous Region (Trial)" .
-
Since the beginning of this year, many domestic and foreign pharmaceutical companies have terminated the development of new drugs
Time of Update: 2022-08-30
It is reported that since the beginning of this year, many pharmaceutical companies have announced the termination of research and development of new drugs .
It is reported that since the beginning of this year, many pharmaceutical companies have announced the termination of research and development of new drugs .
-
A pharmaceutical company committed to potential First-in-Class development plans to be listed on the main board!
Time of Update: 2022-08-30
As of August 11, 2022, QA102 has become one of five small molecule drug candidates for dry age-related macular degeneration that have entered Phase II clinical trials in the world .
-
More than 10 pharmaceutical companies disclosed their semi-annual results, and CRO companies performed well
Time of Update: 2022-08-30
Sanyou Medical achieved operating income of 297 million yuan from January to June 2022, a year-on-year increase of 13.
Sanyou Medical achieved operating income of 297 million yuan from January to June 2022, a year-on-year increase of 13.
-
Jiangxi Province issued a document to relax the basic conditions for selling drugs in supermarkets
Time of Update: 2022-08-30
On June 11 of the same year, 13 departments including the Henan Provincial Department of Commerce also issued the "Implementation Opinions on Promoting the Accelerated Development of Branded Chain Convenience Stores", which clearly stated that brand chain convenience stores can apply for retail operation of Class B non-prescription drugs according to relevant standards, and obtain " Pharmaceutical Business License .
-
Listed pharmaceutical companies launched a wave of mergers and acquisitions: more than 170 mergers and acquisitions during the year, with a total amount of nearly 50 billion yuan
Time of Update: 2022-08-30
Huadong Pharmaceutical announced on August 9 that its wholly-owned subsidiary, Sino-US Huadong, will invest a total of no more than 396 million yuan, and obtain 60% of the equity of Huaren Technology in the form of capital increase and share transfer, becoming its controlling shareholder.
-
A number of pharmaceutical companies announced yesterday, achieving double growth in revenue and net profit
Time of Update: 2022-08-30
According to the 2022 semi-annual report released by Yingkang Life, in the first half of the year, the company's total operating income increased by 7.
According to the 2022 semi-annual report released by Yingkang Life, in the first half of the year, the company's total operating income increased by 7.
-
A batch of Chinese herbal medicine companies were "named"!
Time of Update: 2022-08-30
For example, on August 17, the Anhui Provincial Food and Drug Administration issued an announcement saying that 7 companies of Chinese herbal decoction pieces (including formula granules) had project defects, 5 of which rectified within a time limit, and 2 companies suspended production, admonished, and interviewed; August On the 11th, the Sichuan Food and Drug Administration issued a notice on 6 batches of drugs that did not meet the requirements.
-
From next month, 22 types of medical consumables will drop by nearly 60% on average!
Time of Update: 2022-08-30
From July 1st, Hebei Province has implemented the results of the centralized procurement of high-value medical consumables such as coronary guide catheters and guide wires .
From July 1st, Hebei Province has implemented the results of the centralized procurement of high-value medical consumables such as coronary guide catheters and guide wires .
-
Another batch of pharmaceutical companies such as KingMed Medicine and Shanghai Yizhong disclosed semi-annual reports, most of which achieved performance growth
Time of Update: 2022-08-30
At present, hundreds of pharmaceutical companies have disclosed semi-annual transcripts, and more than half of them have achieved a year-on-year increase in net profit .
At present, hundreds of pharmaceutical companies have disclosed semi-annual transcripts, and more than half of them have achieved a year-on-year increase in net profit .
-
The pace of mergers and acquisitions in the biopharmaceutical industry has accelerated, and domestic pharmaceutical companies have fallen in love with acquiring overseas companies
Time of Update: 2022-08-30
Sihuan Pharmaceutical announced in January that its subsidiary Yaozhong International has acquired the entire equity of Genesis Biosystems in the United States, further expanding the company's medical beauty product pipeline .
-
Novaliq Submits New Drug Application for CyclASol
Time of Update: 2022-08-21
In two pivotal studies, CyclASol® demonstrated rapid onset of therapeutic effect, clinically meaningful improvement in ocular surface damage and excellent tolerability in the indication .
In two pivotal studies, CyclASol® demonstrated rapid onset of therapeutic effect, clinically meaningful improvement in ocular surface damage and excellent tolerability in the indication .
-
BeiGene Announces Positive Results from Global Phase 3 Trial of Tislelizumab in First-Line Unresectable Hepatocellular Carcinoma
Time of Update: 2022-08-21
The company announced today that the RATIONALE 301 study, a global Phase 3 clinical trial of tislelizumab (Chinese brand name: Baizean®), met its primary endpoint in the treatment of adult patients with first-line unresectable hepatocellular carcinoma (HCC).
-
Include Azvudine Tablets in the Novel Coronavirus Pneumonia Diagnosis and Treatment Program
Time of Update: 2022-08-21
All provinces, autonomous regions, municipalities directly under the Central Government and Xinjiang Production and Construction Corps Health and Health Committees and Administration of Traditional C
-
Kintor Pharmaceutical's AR-PROTAC (GT20029) Phase I clinical trial in China completed subject enrollment and administration
Time of Update: 2022-08-21
SUZHOU, Aug. 9, 2022 /PRNewswire/ -- On August 9, 2022, Beijing time, Kintor Pharma, a biopharmaceutical company focused on the development and commercialization of potential first-in-class and best-in-class innovative drugs, announced today that , the China Phase I clinical trial of its self-developed novel androgen receptor (AR)-targeting protein degradation chimera (PROTAC) compound GT20029 in the treatment of androgenetic alopecia and acne has been completed on August 8, 2022 for all 92 Subjects were enrolled and administered .
-
Four departments announced 10 key shortage drug reserve enterprises
Time of Update: 2022-08-21
Pharmaceutical Pharmaceutical Enterprise Enterprise Pharmaceutical Medicine Health and Wellness According to the "Gongxin Weibo" official account on the 9th, the Ministry of Industry and Information Technology, the National Health Commission, the National Medical Security Administration, and the State Drug Administration jointly issued a notice to deploy and strengthen the selection of drugs in short supply and centralized procurement of drugs organized by the state.
-
Announcement of the State Food and Drug Administration on Matters Concerning the Filing of Class I Medical Devices
Time of Update: 2022-08-20
For the filed medical devices, the filing department shall provide the filing number with the filing number (see Annex 3 for the notification of filing number), and publish the "Class I Medical Device Filing Information Form" or "Class I In Vitro Diagnostic Reagent Filing Information" according to the prescribed time.
-
In the past month (July 10-August 10), a large number of pharmaceutical companies in Shanghai and Shenzhen have undergone personnel changes
Time of Update: 2022-08-20
Shuyu civilian: Director resigns Shuyu civilian: Director resigns On August 8, Shuyu Mining announced that the company's board of directors recently received a written resignation application submitted by the company's director, Mr. Li Yubiao, who applied to resign as a non-independent director of the company's third board of directors due to personal reasons, and will no longer hold any positions in the company after resignation.
-
Notice on Printing and Distributing the Design Guidelines for Makeshift Hospitals (for Trial Implementation)
Time of Update: 2022-08-20
、、、、（、）： ，，，，《（）》，。 202276 （：） （ ） 、 1. 1 ，，，，，，。 1. 2 、、。。 1. 3 ，、、、，，，。 1. 4 ，。，、，，。 1. 5 Fangcang shelter hospitals should follow the basic principles of rapid centralized admission, closed-loop p
